IO Biotech to Present at 44th Annual Cowen Health Care Conference
26 Fevereiro 2024 - 6:05PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform, announced today that
Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be
presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO,
will be participating in one-on-one investor meetings at the 44th
Annual Cowen Health Care Conference to be held March 4-6, 2024 in
Boston, MA.
Presentation
DetailsDate and Time: Wednesday, March 6,
2024, 12:50-1:20 PM ESTPresenter: Mai-Britt Zocca,
Ph.D., President & CEOWebcast Link:
https://wsw.com/webcast/cowen154/iobt/2016052
A webcast replay of the presentation will be
available from the Investors section of the Company’s website at
www.iobiotech.com for 90 days.
About IO102-IO103
IO102-IO103 is an investigational therapeutic
cancer vaccine designed to kill both tumor cells and
immune-suppressive cells in the tumor microenvironment (TME) by
stimulating activation and expansion of T cells against indoleamine
2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1)
cells. The company is currently conducting a pivotal Phase 3 trial
(IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in
combination with pembrolizumab versus pembrolizumab alone in
patients with advanced melanoma, a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in
combination with pembrolizumab as first line treatment in patients
with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40;
NCT05280314) investigating IO102-IO103 in combination with
pembrolizumab as neo-adjuvant/adjuvant treatment of patients with
solid tumors.
The clinical trials are sponsored by IO Biotech
and conducted in collaboration with Merck and Merck is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform. The T-win platform is based
on a novel approach to cancer vaccines designed to activate T cells
to target the immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing its lead cancer vaccine
candidate, IO102-IO103, in clinical trials, and additional pipeline
candidates through preclinical development. Based on positive Phase
1/2 first line metastatic melanoma data, IO102-IO103, in
combination with pembrolizumab, has been granted a breakthrough
therapy designation for the treatment of advanced melanoma by the
US Food and Drug Administration. IO Biotech is headquartered in
Copenhagen, Denmark and has US headquarters in New York, New
York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim analysis of our Phase 3 trial,
current or future clinical trials, their progress, enrollment or
results, or the company’s financial position or cash runway, are
based on IO Biotech’s current assumptions and expectations of
future events and trends, which affect or may affect its business,
strategy, operations or financial performance, and actual results
and other events may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Contact:Maryann Cimino,
Director of Investor Relations IO Biotech,
Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
IO Biotech (NASDAQ:IOBT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024